Boston Scientific Co. (NYSE:BSX) Shares Sold by Federated Hermes Inc.

Federated Hermes Inc. lowered its position in Boston Scientific Co. (NYSE:BSX) by 0.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 181,870 shares of the medical equipment provider’s stock after selling 419 shares during the period. Federated Hermes Inc.’s holdings in Boston Scientific were worth $10,514,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in BSX. FMR LLC lifted its position in Boston Scientific by 6.8% in the third quarter. FMR LLC now owns 125,920,357 shares of the medical equipment provider’s stock valued at $6,648,595,000 after purchasing an additional 8,045,263 shares during the period. American Century Companies Inc. lifted its position in shares of Boston Scientific by 391.6% during the 3rd quarter. American Century Companies Inc. now owns 3,271,810 shares of the medical equipment provider’s stock valued at $172,752,000 after acquiring an additional 2,606,253 shares during the period. Wellington Management Group LLP lifted its position in shares of Boston Scientific by 5.9% during the 3rd quarter. Wellington Management Group LLP now owns 42,076,529 shares of the medical equipment provider’s stock valued at $2,221,641,000 after acquiring an additional 2,336,348 shares during the period. Winslow Capital Management LLC lifted its position in shares of Boston Scientific by 39.3% during the 3rd quarter. Winslow Capital Management LLC now owns 6,129,573 shares of the medical equipment provider’s stock valued at $323,641,000 after acquiring an additional 1,730,133 shares during the period. Finally, Vanguard Group Inc. lifted its position in shares of Boston Scientific by 1.2% during the 3rd quarter. Vanguard Group Inc. now owns 123,768,348 shares of the medical equipment provider’s stock valued at $6,534,969,000 after acquiring an additional 1,525,432 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Up 1.4 %

Shares of NYSE BSX opened at $68.99 on Wednesday. Boston Scientific Co. has a 52-week low of $48.35 and a 52-week high of $69.21. The firm has a fifty day moving average of $67.39 and a 200-day moving average of $60.19. The stock has a market capitalization of $101.22 billion, a PE ratio of 64.48, a P/E/G ratio of 2.36 and a beta of 0.78. The company has a quick ratio of 0.82, a current ratio of 1.32 and a debt-to-equity ratio of 0.44.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.51 by $0.04. Boston Scientific had a net margin of 11.19% and a return on equity of 15.99%. The company had revenue of $3.73 billion during the quarter, compared to analysts’ expectations of $3.59 billion. During the same period in the previous year, the company earned $0.45 EPS. On average, analysts anticipate that Boston Scientific Co. will post 2.25 EPS for the current year.

Insider Buying and Selling

In related news, CFO Daniel J. Brennan sold 13,662 shares of the company’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $65.86, for a total transaction of $899,779.32. Following the completion of the sale, the chief financial officer now directly owns 271,542 shares of the company’s stock, valued at approximately $17,883,756.12. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, EVP Wendy Carruthers sold 6,983 shares of the company’s stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $66.89, for a total transaction of $467,092.87. Following the completion of the sale, the executive vice president now directly owns 56,508 shares of the company’s stock, valued at approximately $3,779,820.12. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Daniel J. Brennan sold 13,662 shares of the company’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $65.86, for a total transaction of $899,779.32. Following the sale, the chief financial officer now directly owns 271,542 shares of the company’s stock, valued at $17,883,756.12. The disclosure for this sale can be found here. In the last three months, insiders sold 50,979 shares of company stock valued at $3,418,529. Company insiders own 0.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. StockNews.com downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, March 16th. Argus lifted their price target on shares of Boston Scientific from $69.00 to $80.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. BTIG Research restated a “buy” rating and set a $64.00 price objective on shares of Boston Scientific in a research report on Friday, December 29th. Needham & Company LLC lifted their price objective on Boston Scientific from $60.00 to $71.00 and gave the stock a “buy” rating in a research report on Thursday, February 1st. Finally, Citigroup lifted their price objective on Boston Scientific from $71.00 to $79.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Two research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $68.50.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.